A Global Regulatory Network for Dysregulated Gene Expression and Abnormal Metabolic Signaling in Immune Cells in the Microenvironment of Graves’ Disease and Hashimoto’s Thyroiditis

Haitao Zheng††, Jie Xu††, Yongli Chu††, Wenzhou Jiang‡, Wenjie Yao§, Shaowen Mo§§, Xicheng Song¶ and Jin Zhou§§

1 Department of Thyroid Surgery, Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, China, 2 Department of Clinical Nutrition, Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, China, 3 Department of Scientific Research, Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, China, 4 Department of Neurology, Longkou People’s Hospital, Longkou, China, 5 Department of Endocrinology, Binzhou Medical University, Yantai, China, 6 Department of Basic Science, YuanDong International Academy of Life Sciences, Nanning, China, 7 Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, China, 8 Department of Endocrinology, Affiliated Yantai Yuhuangding Hospital of Qingdao University Medical College, Yantai, China

Background: Although the pathogenetic mechanisms of Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) have been elucidated, the molecular mechanisms by which the abnormal immune function of cellular subpopulations trigger an autoimmune attack on thyroid tissue largely remains unexplained.

Methods: The study included 2 HT patients, 2 GD patients, and 1 control donor. The thyroid samples were extracted for single-cell RNA sequencing, whole transcriptome, full-length transcriptome (Oxford Nanopore Technologies), and metabolome sequencing. Identification of immune cells with dysregulated gene expression and abnormal metabolic signaling was performed in the microenvironment, both at the bulk and single-cell levels. Based on functional enrichment analysis, the biological processes and pathways involved in abnormal immune cells were further explored. Finally, according to cell communication analysis, the global regulatory network of immune cells was constructed.

Results: CD4+ T cells, CD8+ T cells, and macrophages were abnormally increased in patients with HT and GD. The differentially expressed genes of these cells were significantly involved in signaling pathways, including Th1 and Th2 cell differentiation, Th17 cell differentiation, cytokine–cytokine receptor interaction, and NF-κappa B signaling pathway. Moreover, in HT, CD4+ T cells interact with macrophages via the IL16-CCR5/FGF10-FGFR1/CXCL13-CXCR3 axis, and macrophages interact with CD8+ T cells via the CD70-CD27 axis, thereby activating the T-cell receptor signaling pathway and NF-κappa B signaling pathway. In GD, CD4+ T cells interact with macrophages via the CXCR3-
INTRODUCTION

Human autoimmune thyroid disease (AITD) is the most common organ-specific autoimmune disease and the most common cause of thyroid dysfunction and nonendemic goiter, with a global incidence of more than 5% (1–3). AITD mainly manifests as Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), where HT is also known as chronic lymphocytic thyroiditis (CLT) (4). Current understanding suggests that AITD is a result of a complex interaction between genetic, environmental, and endogenous factors leading to loss of self-tolerance to thyroid antigens (5). Described initially in 1912, HT is characterized by increased thyroid volume, diffuse lymphocytic infiltration, and the presence of thyroid antigen-specific antibodies (6). While GD mainly manifests as hypermetabolic syndrome caused by hyperthyroidism and is accompanied by goiter, ocular signs, and pretibial myxedema (7). Collectively, AITD has varying clinical manifestations, including euthyroidism, clinical and subclinical hyperthyroidism caused by HT, clinical or subclinical hyperthyroidism of GD, and the mutual transformation of hyperthyroidism and hypothyroidism. Although HT and GD have distinct clinical features, they are identical in terms of tissue damage, including in vivo lymphocyte infiltration.

In HT, lymphocyte infiltration leads to thyroid cell apoptosis and hypothyroidism (8). In GD, however, similar lymphocytic infiltration results in activation of thyroid-stimulating hormone receptor (TSHR)-responsive B cells, which secrete TSHR-stimulating antibodies (TRAb). Interaction between pathogenic TRAb and TSHR, located on the thyroid follicular epithelial cell membrane, triggers an autoantigen-antibody response that leads to diffuse enlargement of thyroid tissue and excessive secretion of thyroid hormones (9). Studies have demonstrated that T lymphocytes and their specific cytokines, an indispensable part of immunity, play a critical role in the occurrence of AITD. Though infiltration of T lymphocytes leads to direct destruction of thyroid tissue, it is the presence of other T-cell subsets that synthesize proinflammatory cytokines to maintain and amplify the extent of autoimmune responses (10–13). Evolving literature elucidates the powerful role of distinct T-cell subsets in AITD, and these immunologically abnormal T-cell subsets may lead to autoimmunity to thyroid tissue (14). For example, dysregulation of regulatory T cells (Tregs) and helper T cells (Th17) may stimulate the production of thyroid-stimulating antibody (TSAb), suggested as one of the factors involved in pathogenesis of GD (15, 16). In addition, Th1/Th2 imbalance also plays a key role in the pathogenesis of both HT and GD (17). While, Th1-dominated immune activity may promote apoptosis of thyroid follicular cells, leading to destruction of thyroid cells and ultimately HT, a predominant Th2-mediated immune response induces antigen-specific B lymphocyte production (TRAb), leading to GD (18, 19). However, the molecular mechanism by which the immune dysfunction of these cell subsets leads to autoimmune destruction of thyroid tissue remains largely unexplained.

In this study, based on the single-cell RNA sequencing, whole transcriptome sequencing, full-length transcriptome sequencing, and metabolome sequencing data of HT and GD, we explored the immune cells with dysregulated gene expression and abnormal metabolic signaling in the microenvironment of HT and GD, thereby constructing a global regulatory network of immune cells. This provides scientific theoretical guidance and a research basis for further understanding of the disease mechanisms mediated by immune disorders and metabolic abnormalities in HT and GD and for better intervention and treatment of the disease.

METHOD

Human Sample

The study included 2 HT patients, 2 GD patients, and 1 control donor. All the patients and the control donor agreed to a multisample library and sequencing protocol covering all study procedures. The study protocol was approved by the ethics review board of Yantai Yuhuangding Hospital. Demographic and clinical data are presented in Supplementary Table S1. According to the study requirement, thyroid lesions were obtained from HT and GD patients, and paranasal tissue was obtained from the control donor (who underwent surgery for suspected malignant thyroid nodules) for sequencing. RNA samples were extracted by Trizol (Thermo Fisher Scientific, Waltham, MA, USA). All sequencing was performed at Biomarker Technologies Corporation (Beijing, China).

Single-Cell Transcriptome Sequencing

Sample preparation and cDNA library construction were performed as described in the 10x Genomics Single Cell 3’v3.1 Kit User Guide. The cDNA product and library concentrations were detected according to the qubit 4.0 fluorescence quantitative instrument, and the insertion fragment size of cDNA library was detected by qseq400 biological analyzer. Finally, the sample library was sequenced using novaseq 6000.
After recognizing Casava base, the obtained original image file was converted into a sequence file and stored in fastq format. The 10x genomics official software CellRanger was then used to compare and quantify the sequencing data.

Whole Transcriptome Sequencing
For long noncoding RNA (lncRNA) sequencing, at the request of the manufacturer, the sequencing library was generated using the NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® (NEB, Beverly, MA, USA), and the index code was added to the attribute sequence of each sample. The TruSeq SR Cluster Kit v3-cBot-HS (Illumina, San Diego, CA, USA) was used to cluster the index coding samples on the cBot Cluster Generation System. Following cluster generation, the library preparation was sequenced on Illumina Hiseq platform and double terminal readings were generated. The raw data obtained were stored in fastq format. The transcriptome was then assembled using StringTie (20), based on the readings mapped to the reference genome. The assembled transcripts were annotated using the gffcompare program (21).

For microRNA (miRNA) sequencing, small RNA libraries were constructed and library quality was assessed according to the manufacturer’s instructions. Subsequently, the clustering of the index-coded samples was performed on a cBot Cluster Generation System using the TruSeq PE Cluster Kit v4-cBot-HS (Illumina, San Diego, CA, USA). Following cluster generation, the library preparations were sequenced on an Illumina platform and single-end readings were generated. The raw data obtained were stored in fastq format. Considering Homo_sapiens.GRCCh38.release95 as the reference genome, the unannotated readings were aligned with the reference genome using the Bowtie software (22).

Full-Length Transcriptome Sequencing
The total RNA (1 µg) was prepared for the cDNA library using the cDNA PCR Sequencing Kit (SQK-PCS109) protocol provided by Oxford Nanopore Technologies (ONT). The cDNA library was added to FLO-MIN109 flowcells and run on the Promethion platform. The Guppy software in the MinKNOW2.2 software package was used for base calling, and the fast5 format data was converted to fastq format for storage. Subsequently, the full-length sequence was aligned with the reference genome using minimap2 software (23). Following clustering through the alignment information, the consensus sequence was obtained using pinfish software. The consensus sequences of each sample were merged and aligned with the reference genome through minimap2.

Metabolome Sequencing
Metabolites were extracted from the samples, and supernatants were isolated for sequencing, as required for the experiment. The LC/MS system for metabolomics analysis was composed of Waters Acquity I-Class PLUS ultra-high performance liquid tandem Waters Xevo G2-XS QT of high-resolution mass spectrometer. The column used was purchased from the Waters Acquity UPLC HSS T3 column (1.8 µm, 2.1 × 100 mm).

The positive ion mode consisted of mobile phase A (0.1% formic acid aqueous solution) and mobile phase B (0.1% formic acid acetonitrile). Similarly, negative ion mode consisted of mobile phase A (0.1% formic acid aqueous solution) and mobile phase B (0.1% formic acid acetonitrile). Moreover, the injection volume was 1 µl.

Subsequently, the raw data collected with MassLynx V.4.2 were processed by Progenesis QI for peak extraction, peak alignment, and other data processing operations, based on the Progenesis QI online METLIN database (24) and Biomark’s self-built library for identification, and at the same time, theoretical fragment identification and mass deviation. All were within 100 parts per million (ppm). Further analysis was performed after normalizing the original peak area information with the total peak area.

Differential Expression Analysis
To explore the dysregulated genes of HT and GD, we performed differential expression analysis with the Limma package (25), and p < 0.05 and |log fold change (logFC)| >0.5 were considered significant.

Functional Enrichment and Gene Enrichment Analysis
To further explore the biological processes (BP) and pathways involved in dysregulated genes, differentially expressed genes (DEGs) were subjected to BP analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using the clusterProfiler package in R language (26); p < 0.05 were considered significant.

Moreover, using the c2.cp.kegg.v6.2.symbols.gmt in the MsigDB V6.2 database (27) as the background set, the DEGs were subjected to Gene Enrichment Analysis (GSEA) (28). GSEA was performed using clusterProfiler package; p < 0.05 were considered significant.

Immune Infiltration Analysis
With reference to a study by Charoentong et al. (29), immune infiltration analysis was performed using the GSEA method to evaluate the differences in immune infiltration between GD and HT patients and control donor, with special focus on cells with high degree of similarity toAITD, such as T cells, T helper cells, and macrophages.

Construction of Single-Cell Atlas
The IntegrateData function of the Seurat package for R language (30) was used to merge single-cell data, and cell clustering analysis was performed according to the default parameters. The clustering results were uniformly reduced and visualized using PCA and T distributions and Stochastic Nearest-Neighbor Embedding (t-SNE), projected onto a 2-dimensional image, defined as a single-cell atlas. Moreover, the FindMarkers function of the Seurat package was used to identify DEGs for each cluster, and p < 0.05 and |logFC| >0.5 were considered significant. In addition, cell-type annotation was performed according to the known markers (Supplementary Table S2).

Intercellular Communication Analysis
Ligand-receptor binding is one of the main forms of intercellular signal transduction. Therefore, we performed the cell
communication analysis with the iTALK package in R (31). iTALK works by identifying highly or differentially expressed genes in cell clusters, with subsequent matching and pairing of these genes through a ligand receptor database to find important intercellular communication events.

**Reverse Transcription-Quantitative Polymerase Chain Reaction Analysis**

The DEGs involved in the HT and GD regulatory networks were validated by quantitative polymerase chain reaction (qPCR). Trizol (Thermo Fisher Scientific, Waltham, MA, USA) was used to lyse tissues and extract total RNA. The cDNA was then synthesized according to the instructions of the kit (Tiangen, Beijing, China), and the qPCR reaction system was prepared by the qPCR Kit (Gene Star, Beijing, China), in which 2×q-PCR Mix 10 μl, upstream and downstream primers 0.5 μl each, replenish water to 20 μl. Finally, qPCR was performed using Applied Biosystems Stepone plus real-time quantitative PCR instrument (Thermo Fisher Scientific, Waltham, MA, USA) with the following conditions: predenaturation at 95°C for 1 min, followed by 40 cycles of 95°C for 15 s and 60°C for 15 s. The primers used in this study are shown in Supplementary Table S3.

**Data Analysis and Statistics**

In this study, all analyses were performed based on the Bioinforcloud platform (http://www.bioinforcloud.org.cn).

**RESULT**

**Patterns of Gene Expression Dysregulation in HT and GD at the Bulk Level**

The study flowchart is illustrated in Figure 1. To identify aberrantly expressed lncRNAs and miRNAs in HT and GD patients, differential expression analysis of ONT sequencing and RNA sequencing data was performed (Supplementary Table S4). On analysis, 6,153 lncRNAs and 741 miRNAs were found to be differentially expressed among HT patients (Figure 2A). Similarly, 5,492 lncRNAs and 165 miRNAs were observed to be differentially expressed among GD patients (Figure 2B). Moreover, the findings of correlation analysis validated the robustness of both sequencing methods used in this study (Figures 2C, D). Finally, we could extract genes with high confidence of dysregulated expression among HT and GD patients for follow-up analysis (Figures 2E, F).

**Dysregulated Gene Expression in HT and GD Is Associated With Abnormal Immune Cascades and Metabolic Signaling**

To identify the molecular dysregulation mechanisms associated with HT and GD, we extracted high-confidence dysregulated genes expressed in HT and GD for enrichment analysis (Figure 1). HT was found to have significant leukocyte–cell adhesion, T-cell activation and differentiation, cytokine metabolic processes, and immune response-activated signal transduction of BP (Figure 3A). While, in GD, leukocyte–cell adhesion, hormone metabolic processes, and cell chemotaxis of BP were found to be significantly enriched (Figure 3B). Moreover, the KEGG signaling pathway associated with thyroid disease was found to be enriched in both HT (Figure 3C) and GD (Figure 3D). These include parathyroid hormone synthesis, secretion of thyroid hormone, and action of thyroid hormone signaling pathways and autoimmune thyroid diseases. Simultaneously, several other immune-inflammatory and metabolic signaling-related pathways were enriched in both HT and GD, including cytokine–cytokine receptor interactions, chemokine signaling pathways, Th1 and Th2 cell differentiation, NF-kappa B signaling pathways, phenylalanine metabolism, tryptophan metabolism, and tyrosine metabolism.

To further determine the role of metabolites in HT and GD, we identified differential metabolites in HT (Figure 3E) and GD (Figure 3F) relative to controls. The differential metabolites were subjected to metabolic pathway enrichment analysis, which revealed that the metabolic pathways of phenylalanine, tyrosine and tryptophan biosynthesis, phenylalanine metabolism, and steroid biosynthesis were significantly activated in HT [Figure 3G(a)], while the metabolic pathways of linoleic acid metabolism and steroid hormone biosynthesis were inhibited [Figure 3G(b)]. Moreover, steroid hormone biosynthesis, caffeine metabolism, and arachidonic acid metabolic pathways were activated in GD [Figure 3G(c)], while phenylalanine, tyrosine and tryptophan biosynthesis, and linoleic acid metabolic pathways were inhibited [Figure 3G(d)].

Given the important role of immune responses in HT and GD, we further evaluated the abundance of immune cells in the samples (Figure 3H), with varying degrees of infiltration of CD4+ T, CD8+ T, Mac, Th1, and Th2 cells.

**Dysregulated Gene Expression and Abnormal Metabolic Signaling in Microenvironmental CD4+ T Cells in HT and GD**

To further understand the effect of dysregulated gene on disease at the cellular level, the abundance of CD4+ T cells in HT, GD, and control samples was explored, which are illustrated in Figure 4A. Moreover, we identified the genes that were co-overexpressed with high confidence dysregulation at the bulk level and in CD4+ T cells and explored the biological signatures involved in these co-disordered genes. In HT, these co-disordered genes were significantly involved in the thyroid hormone signaling pathway, T-cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, cytokine–cytokine receptor interactions, and NF-kappa B signaling pathway (Figure 4B). While, in GD, parathyroid hormone synthesis, secretion and action, ECM–receptor interactions, purine metabolism, cAMP signaling pathway, NF-kappa B signaling pathway, cytokine–cytokine receptor interactions, and T-cell receptor signaling pathway were significantly enriched (Figure 4C). In HT, GSEA demonstrated significant enrichment of cytokine–cytokine receptor interactions and T-cell receptor signaling pathways.
Moreover, some dysregulated metabolic signaling pathways including amino acid biosynthesis and purine metabolism were found to be significantly enriched in both HT (Supplementary Figure S1A) and GD (Supplementary Figure S1B).

**Dysregulated Gene Expression and Abnormal Metabolic Signaling in Microenvironmental CD8$^+$ T Cells in HT and GD**

The abundance of CD8$^+$ T cells in HT, GD, and control is illustrated in Figure 5A. We identified genes that were co-overexpressed with high confidence dysregulation, both at the bulk level and in CD8$^+$ T cells, and evaluated the biological signals involved in these co-disordered genes. In both HT (Figure 5B) and GD (Figure 5C), these co-disordered genes were substantially involved in antigen processing and presentation, Th1 and Th2 cell differentiation, Th17 cell differentiation, cytokine–cytokine receptor interactions, and NF-kappa B signaling pathway. In particular, synthesis, secretion, and action of parathyroid hormone as well as leukocyte migration pathways across the endothelium were enriched in HT. In GD, purine metabolism and cAMP signaling pathways were substantially enriched. In HT, GSEA revealed significant enrichment of cytokine–cytokine receptor interactions and NF-kappa B signaling pathways (Figure 5D), while similar enrichment was not observed in GD. However, purine metabolic signaling pathways were enriched in both HT (Figure S2A) and GD (Figure S2B).

**Dysregulated Gene Expression and Abnormal Metabolic Signaling in Microenvironmental Mac Cells in HT and GD**

In particular, we found significant differences in the abundance of Mac cells in HT, GD, and control (Figure 6A). By exploring the biological signatures involved in genes with high confidence of dysregulated expression at the bulk level and in Mac cells, in both HT (Figure 6B) and GD (Figure 6C), we observed significant involvement of these co-disordered genes in...
synthesis, secretion, and action of parathyroid hormone, antigen processing and presentation, Th1 and Th2 cell differentiation, Th17 cell differentiation, NOD-like receptor signaling pathway, the NF-kappa B signaling pathway, and cytokine–cytokine receptor interactions. While in HT, the thyroid hormone signaling pathways and Toll-like receptor signaling pathways were significantly enriched. Phagosomal, phenylalanine, tyrosine, and tryptophan biosynthetic pathways were found to be significantly enriched in GD. In HT, GSEA revealed significant enrichment of cytokine–cytokine receptor interactions, NF-kappa B signaling pathway, Th1 and Th2 cell differentiation, and Th17 cell differentiation pathways (Figure 6D), while similar enrichment was absent in GD. Moreover, the purine and phenylalanine metabolic signaling pathways were enriched in HT (Supplementary Figure S3A) and GD (Supplementary Figure S3B), respectively.
Global Regulatory Network of T Cells and Macrophages in the Microenvironment of HT and GD

To determine the mechanism of intercellular regulation of the microenvironment of HT and GD, we analyzed the intercellular communication of CD4+ T, CD8+ T, and Mac cells. This led us to explore the differentially expressed ligands and receptors in different cell types, thereby allowing us to construct a comprehensive regulatory network that might be the mechanism leading to HT and GD. iTALK analysis revealed the presence of a significant
difference in the abundance of ligand–receptor pairs in both HT (Figure 7A) and GD (Figure 7B). Finally, we mapped the regulatory network of dysregulated gene expression between microenvironmental T cells and macrophages in HT and GD. In HT, microenvironmental T cells target macrophages via the IL16-CCR5 axis, FGF10-FGFR1 axis, CXCL13-CXCR3 axis, and CD70-CD27 axis, activating cytokine–cytokine receptor interactions and T-cell receptor signaling pathways (Figure 7C), whereas, in GD, microenvironmental T cells target macrophages via the CXCR3-CXCL10 axis, PKM-CD44 axis, and CCL21-CCR7 axis, activating EMC receptor interaction and NF-kappa B signaling (Figure 7D). Furthermore, qPCR confirmed that some of the genes involved in the HT (Figure 7E) and GD (Figure 7F) regulatory networks were differentially expressed compared to the control.

**DISCUSSION**

Previous studies have shown that abnormal immune cells may play a key role in the induction of HT and GD (17–19). In this study, based on the bulk level, we identified the dysregulated genes in HT and GD patients. Simultaneously, we observed that these genes are mainly involved in Th1 and Th2 cell differentiation, Th17 cell differentiation, and the NF-kappa B signaling pathway, as reported in previous studies. In HT patients, infiltration of the thyroid gland by Th17 cells significantly raised serum IL-17 levels (32), and the imbalance of Th1/Th17 differentiation of peripheral blood mononuclear cells may be associated with the pathogenesis of HT (33). In particular, the differentiation of Th17 lymphocytes and the
synthesis of Th17 cytokines were found to be enhanced in AITD and HT, respectively (34). Moreover, we observed that HT patients had an imbalance of Th1/Treg, Th2/Treg, and Th17/Treg lymphocytes at the level of transcription factors and shifted towards Th1, Th2, and Th17 cells, respectively (35). In GD patients, the NF-kappa B signaling pathway was found to be significantly activated (36). The pathogenesis of GD may be related to the reduced Tregs and the increased IL-17 gene expression (37). This demonstrates that HT and GD patients have abnormal immune cells.

Furthermore, by combining transcriptome and metabolome, we identified immune cells with dysregulated gene expression and abnormal metabolic signaling in the microenvironment of HT and GD patients at the single-cell level. In both GD and HT, phenylalanine, tyrosine, and tryptophan biosynthesis were significantly activated, while linoleic acid metabolism and one carbon pool by folate were inhibited. We also observed that CD4⁺ T cells, CD8⁺ T cells, and macrophages were abnormally higher in HT. Similarly, CD4⁺ T cells and CD8⁺ T cells were abnormally higher in GD. Studies have reported that the cellular immune process mediated by CD4⁺ and CD8⁺ lymphocyte subsets plays an important role in the pathogenesis of HT (38). In contrast, GD revealed an increase in both CD4⁺ and CD8⁺ T cells, while HT revealed a reduced number of CD4⁺ T cells and an increase in CD8⁺ T cells (39). Moreover, cytokines produced by macrophages, T cells, and thyroid follicular cells play an important role in HT, especially in the development and perpetuation of autoimmune diseases (40).

To further explore the molecular mechanisms involved in dysregulated immune cells, we explored the biological and metabolic signaling pathways involved in significantly dysregulated genes in CD4⁺ T cells, CD8⁺ T cells, and macrophages at single-cell level. Similar to the bulk level, together, these cells were significantly involved in pathways such as Th1 and Th2 cell differentiation, Th17 cell differentiation, and NF-kappa B signaling. Among them, the NF-kappa B signaling pathway has long been regarded as a typical proinflammatory signaling pathway (41), and NF-kappa B is a key signaling element of autoimmunity and an important target for the treatment of autoimmune diseases (42).

Thus, activation of this pathway suggests an inflammatory response in patients, which may be a sign of immune dysregulation.

Subsequently, based on cellular communication analysis, we constructed a global regulatory network of dysregulated immune
cells in HT and GD patients and observed extensive intercellular communication between CD4⁺ T cells, CD8⁺ T cells, and macrophages. Notably, these cells can interact with chemokine receptors and ligands such as CXCR3-CXCL13, CXCR3-CXCL10, and CCR7-CCL21. Among them, CXCR3 and its chemokines CXCL10, CXCL9, and CXCL11 are widely involved in the pathogenesis of autoimmune diseases such as HT, GD, thyroid eye disease (TED), type 1 diabetes, and autoimmune Addison’s disease, and may be potential targets for new drugs to treat these diseases (43, 44). CCL21, a chemokine that regulates homeostatic lymphocyte migration, is involved in lymphocyte migration to the thyroid gland (45) and is important for the circulation of CCR7-expressing cells, making it a potential target for TRAb-positive GD therapy (46). Moreover, chemokines have important effects on the polarization of macrophages. Traditionally, macrophages are categorized as (47) classically activated (M1) macrophages and alternately activated (M2) macrophages. Among them, M1 macrophages exhibit greater immune functions, while M2 macrophages exhibit greater immunosuppressive functions (48). The polarization of M1 and M2 macrophages is regulated by different chemokines (49). It is speculated that, due to the influence of specific chemokines, HT and GD promote the polarization of macrophages to M1 type, resulting in transitional immunity. It is further suggested that dysregulation of Th1 and Th2 cell differentiation has critical effects on macrophages. Stimulation of resting macrophages (M0 macrophages) with Th1 cytokines (IFNγ) or TLR4 ligands (LPS) has been demonstrated to induce classic M1 polarization (50). Conversely, a Th2 cytokine (IL-4) induces alternating polarization of M2 macrophages (50). This suggests the dysfunctional nature of the immune cells in patients with HT and GD. Moreover, the interaction between cells also activates associated immune pathways and triggers transitional immunity, thereby inducing the immune cells to target thyroid tissue.

Though this study reports novel findings, it has certain limitations. First, the sample included in this study was relatively small, and the analytical results obtained require further validation in a large sample. Second, although the mechanism derived in this study is based on scientific bioinformatics analytical methods, it has not been verified by molecular and cellular experiments. Thus, we
FIGURE 7 | Global regulatory network of microenvironmental T cells and macrophages in HT and GD. (A, B) Global regulatory network of communication between microenvironmental T cells and macrophages in HT (A) and GD (B) patients. Circles represent ligand genes, triangles represent receptor genes, hexagons represent miRNAs, diamonds represent TFs, and V shapes represent signaling pathways. (C, D) In HT (C) and GD (D) patients, the global dysregulation mechanism of microenvironmental T cells and macrophages. (E, F) qPCR of genes involved in HT (E) and GD (F) regulatory networks. GD, Graves’ disease; HT, Hashimoto’s thyroiditis. ****P < 0.0001.
plan to further expand the sample range in future studies and use molecular and cellular experiments to verify the findings.

In conclusion, this study used the combination of the transcriptome and metabolome to identify immune cells with dysregulated gene expression and abnormal metabolic signaling in the microenvironment of HT and GD at the single-cell level. Simultaneously, we constructed a global regulatory network of these cells, contributing to immune dysregulation and metabolic abnormalities mediated by HT and GD disease mechanisms to provide a new perspective.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The name of the repository and accession number can be found below: National Genomics Data Center (https://ngdc.cncb.ac.cn/); HRA002138.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Yantai Yuhuangding Hospital. The patients/participants provided their written informed consent to participate in this study.

REFERENCES

1. Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune Thyroid Disorders. Autoimmun Rev (2015) 14(2):174–80. doi: 10.1016/j.autrev.2014.10.016
2. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The Incidence of Thyroid Disorders in the Community: A Twenty-Year Follow-Up of the Whickham Survey. Clin Endocrinol (Oxf) (1995) 43(1):55–68. doi: 10.1111/j.1365-2265.1995.tb01894.x
3. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States. Clin Immunol Immunopathol (1997) 84(3):223–43. doi: 10.1006/clim.1997.4412
4. Idah MA, Macharia BN. Autoimmune Thyroid Disorders. ISRN Endocrinol (2013) 2013:509764. doi: 10.1155/2013/509764
5. Kyritsi EM, Kanaka-Gantenbein C. Autoimmune Thyroid Disease in Specific Genetic Syndromes in Childhood and Adolescence. Front Endocrinol (Lausanne) (2020) 11:543. doi: 10.3389/fendo.2020.00543
6. Ralli M, Angeletti D, Fiore M, D’Aguanno V, Lambiase A, Artico M, et al. Hashimoto’s Thyroiditis: An Update on Pathogenic Mechanisms, Diagnostic Protocols, Therapeutic Strategies, and Potential Malignant Transformation. Autoimmun Rev (2020) 19(10):102649. doi: 10.1016/j.autrev.2020.102649
7. McLachlan SM, Nagayama Y, Ra poport B. Insight Into Graves’ Hyperthyroidism From Animal Models. Endocr Rev (2005) 26(6):800–32. doi: 10.1210/er.2004-0023
8. Weetman A. Chronic Autoimmune Thyroiditis. In: Le Braverman, Rd Utiger, editors. Werner and Ingbar’s the Thyroid. Philadelphia: Lippincott Williams and Wilkins (2000).
9. Shoenfeld Y, Cervera R, Gershwin ME. Diagnostic Criteria in Autoimmune Diseases. (2010).
10. Guan LJ, Wang X, Meng S, Shi LF, Jiang WJ, Xiao L, et al. Increased IL-21/IL-21r Expression and Its Proinflammatory Effects in Autoimmune Thyroid Disease. Cytokine (2015) 72(2):160–5. doi: 10.1016/j.cytto.2014.11.005
11. McLachlan SM, Ra poport B. Breaking Tolerance to Thyroid Antigens: Changing Concepts in Thyroid Autoimmunity. Endocr Rev (2014) 35(1):59–105. doi: 10.1210/er.2013-1055
12. Mikos H, Mikos M, Obara-Moszynska M, Niedziela M. The Role of the Immune System and Cytokines Involved in the Pathogenesis of Autoimmune Thyroid Disease (Aitd). Endokrynol Pol (2014) 65(2):150–5. doi: 10.5603/ EP.2014.0021
13. Li H, Wang T. The Autoimmunity in Graves’s Disease. Front Biosci (Landmark Ed) (2013) 18:792–7. doi: 10.2741/4141
14. Li Q, Wang B, Mu K, Zhang JA. The Pathogenesis of Thyroid Autoimmune Diseases: New T Lymphocytes - Cytokines Circuits Beyond the Th1-Th2 Paradigm. J Cell Physiol (2019) 234(3):2204–16. doi: 10.1002/jcp.27180
15. Grant CR, Liberal R, Mieli-Vergani G, Vergani D, Longhi MS. Regulatory T-Cells in Autoimmune Diseases: Challenges, Controversies and—Yet—Unanswered Questions. Autoimmun Rev (2015) 14(2):105–10. doi: 10.1016/j.autrev.2014.10.012
16. Zuniga LA, Jain R, Haines C, Cua DJ. Th17 Cell Development: From the Cradle to the Grave. Immunol Rev (2013) 252(1):78–88. doi: 10.1111/imr.12036
17. Zaletel K, Gabersek S. Hashimoto’s Thyroiditis: From Genes to the Disease. Curr Genomics (2011) 12(8):576–88. doi: 10.2174/138920211798120763
18. Eshaghkhani Y, Sanati MH, Nakhjavani M, Safari R, Khajavi A, Ateai M, et al. Disturbed Th1 and Th2 Balance in Patients With Graves’ Disease. Minerva Endocrinol (2016) 41(1):28–36.
19. Tsatsoulis A. The Role of Stress in the Clinical Expression of Thyroid Autoimmunity. Ann N Y Acad Sci (2006) 1088:382–95. doi: 10.1196/ annals.1366.015
20. Perta e, Perta e GM, Antonesc u CM, Chang TC, Mendell JT, Salzberg SL. Stringite Enables Improved Reconstruction of a Transciptome From Rna-Seq Reads. Nat Biotechnol (2015) 33(3):290–5. doi: 10.1038/nbt.3122
21. Perta e, Perta e M. Gif Utilities: Gfread and Gffcompare. Filter000Res (2020) 9. doi: 10.12688/f1000research.23297.2
22. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and Memory-Efficient Alignment of Short DNA Sequences to the Human Genome. Genome Biol (2009) 10(3):R25. doi: 10.1186/gb-2009-10-3-25
23. Li H. Minimap2: pairwise Alignment for Nucleotide Sequences. Bioinformatics (2018) 34(18):3094–100. doi: 10.1093/bioinformatics/bty191
24. Gu jia C, Montenegro-Burke JR, Domingo-Almenara X, Palermo A, Warth B, Hermann G, et al. Melin: A Technology Platform for Identifying Knowns and
Unkowns. Anal Chem (2018) 90(5):3156–64. doi: 10.1021/acs.analchem.7b04424

25. Umezawa KE, Phibson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma Powers Differential Expression Analyses for RNA-Seqencing and Microarray Studies. Nucleic Acids Res (2015) 43(7):e47. doi: 10.1093/nar/gkv007

26. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: An R Package for Comparing Biological Themes Among Gene Clusters. OMICS (2012) 16(5):284–7. doi: 10.1089/omi.2011.0118

27. Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (Msigdb) Hallmark Gene Set Collection. Cell Syst (2015) 1(6):417–25. doi: 10.1016/j.celrep.2015.12.004

28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles. Proc Natl Acad Sci USA (2005) 102(43):15545–50. doi: 10.1073/pnas.0506580102

29. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-Cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep (2017) 18(1):248–62. doi: 10.1016/j.celrep.2016.12.019

30. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating Single-Cell Transcriptomic Data Across Different Conditions, Technologies, and Species. Nat Biotechnol (2018) 36(5):411–20. doi: 10.1038/nbt.4096

31. Wang Y, Wang R, Zhang S, Song S, Jiang C, Han G, et al. iTALK: An R Package to Characterize and Illustrate Intercellular Communication. bioRxiv (2019). Available at: https://www.biorxiv.org/content/10.1101/507871v1.

32. Li D, Cai W, Gu R, Zhang Y, Zhang H, Tang K, et al. Th17 Cell Plays a Role in the Pathogenesis of Hashimoto’s Thyroiditis in Patients. Clin Immunol (2013) 149(3):411–20. doi: 10.1016/j.clim.2013.10.001

33. Shi Y, Wang H, Su Z, Chen J, Xue Y, Wang S, et al. Differentiation Imbalance of Th1/Th17 in Peripheral Blood Mononuclear Cells Might Contribute to Pathogenesis of Hashimoto’s Thyroiditis. Scand J Immunol (2010) 72(3):250–5. doi: 10.1111/j.1365-3083.2010.02425.x

34. Figueroa-Vega N, Alfonso-Perez M, Benedicto I, Sanchez-Madrid F, Gonzalez-Amaro R, Marazuela M. Increased Circulating Pro-Inflammatory Cytokines and Th17 Lymphocytes in Hashimoto’s Thyroiditis. J Clin Endocrinol Metab (2010) 95(2):953–62. doi: 10.1210/jc.2009-1719

35. Safdari V, Alijani E, Nemati M, Jafarzadeh A. Imbalances in T Cell-Related Transcriptomic Data Among Patients With Hashimoto’s Thyroiditis. Sultan Qaboos Univ Med J (2017) 17(2):e174–e80. doi: 10.18295/squmj.2016.17.02.007

36. Yin Q, Shen L, Qi Y, Song D, Ye L, Peng Y, et al. Decreased Sirt1 Expression in the Peripheral Blood of Patients With Graves’ Disease. J Endocrinol (2020) 246(2):161–73. doi: 10.1530/JOE-19-0501

37. Yuan Q, Zhao Y, Zhu X, Liu X. Low Regulatory T Cell and High B-17 mRNA Expression in a Mouse Gravess’ Disease Model. J Endocrinol Invest (2017) 40(4):397–407. doi: 10.1007/s40618-016-0575-9

38. Weetman AP. Autoimmune Thyroid Disease: Propagation and Progression. Eur J Endocrinol (2003) 148(1):1–9. doi: 10.1530/eje.0.1480001

39. Ben-Skowronek I, Szewczyk L, Kulik-Rechberger B, Korobowicz E. The Differences in T and B Cell Subsets in Thyroid of Children With Graves’ Disease and Hashimoto’s Thyroiditis. World J Pediatr (2013) 9(3):245–30. doi: 10.1007/s12519-013-0398-0

40. Ajjan RA, Watson PF, McIntosh RS, Weetman AP. Intrathyroidal Cytokine Gene Expression in Hashimoto’s Thyroiditis. Clin Exp Immunol (1996) 105(3):523–8. doi: 10.1111/j.1365-2249.1996.tb14989.x

41. Lawrence T. The Nuclear Factor NF-KappaB Pathway in Inflammation. Cold Spring Harb Perspect Biol (2009) 1(6):a001651. doi: 10.1101/cshperspect.a001651

42. O’Sullivan B, Thompson A, Thomas R. NF-Kappa B as a Therapeutic Target in Autoimmune Disease. Expert Opin Ther Targets (2007) 11(2):111–22. doi: 10.1517/14728222.11.2.111

43. Fallahi P, Ferrari SM, Elia G, Nasini F, Colaci M, Giuggioli D, et al. Novel Therapies for Thyroid Autoimmune Diseases. Expert Rev Clin Pharmacol (2016) 9(6):853–61. doi: 10.1586/17512433.2016.1157468

44. Fallahi P, Ferrari SM, Ragusa F, Ruffilli I, Elia G, Paparo SR, et al. Th1 Chemokines in Autoimmune Endocrine Disorders. J Clin Endocrinol Metab (2020) 105(4):dgz289. doi: 10.1210/clinendim/dgz289

45. Martin AP, Coronel EC, Sano G, Chen SC, Vassileva G, Canasto-Chibucque C, et al. A Novel Model for Lymphocytic Infiltration of the Thyroid Gland Generated by Transgenic Expression of the Cc Chemokine Ccl21. J Immunol (2004) 173(8):4791–8. doi: 10.4049/jimmunol.173.8.4791

46. Qi Y, Li X, Zhang Q, Huang F, Lin D, Zhou Y, et al. Increased Chemokine (C-C Motif) Ligand 21 Expression and Its Correlation With Osteopontin in Graves’ Disease. Endocrine (2015) 50(1):123–9. doi: 10.1007/s12020-015-0552-7

47. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes. Trends Immunol (2002) 23(11):549–55. doi: 10.1016/s1471-4906(02)02302-5

48. Ruytinx P, Proost P, Van Damme J, Struyf S. Chemokine-Induced Macrophage Polarization in Inflammatory Conditions. Front Immunol (2018) 9:1930. doi: 10.3389/fimmu.2018.01930

49. Xuan W, Qu Q, Zheng B, Xiong S, Fan GH. The Chemotaxis of M1 and M2 Macrophages Is Regulated by Different Chemokines. J Leukoc Biol (2015) 97(1):61–9. doi: 10.1189/jlb.1A0314-170R

50. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goedert S, et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity (2014) 41(1):14–20. doi: 10.1016/j.immuni.2014.06.008

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zheng, Xu, Chu, Jiang, Yao, Mo, Song and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.